|
Scale
|
ASTERIA I
|
ASTERIA II
|
GLACIAL
|
|---|
|
Placebo
|
Omalizumab 75 mg
|
Omalizumab 150 mg
|
Omalizumab 300 mg
|
Placebo
|
Omalizumab 75 mg
|
Omalizumab 150 mg
|
Omalizumab 300 mg
|
Placebo
|
Omalizumab 300 mg
|
|---|
|
MOS-Sleep Scale, SPI-II, n
|
80
|
77
|
80
|
81
|
79
|
82
|
82
|
79
|
83
|
252
|
|
Mean (SD)a
|
47.8 (19.8)
|
48.4 (17.8)
|
49.2 (21.2)
|
47.4 (19.3)
|
47.4 (18.1)
|
48.0 (18.6)
|
48.5 (18.6)
|
47.8 (17.8)
|
47.9 (18.6)
|
49.1 (18.9)
|
|
UPDD Weekly Sleep Interference Score, n
|
80
|
77
|
80
|
81
|
79
|
82
|
82
|
79
|
83
|
252
|
|
Mean (SD)
|
12.6 (4.8)
|
12.2 (5.3)
|
12.1 (5.2)
|
12.2 (4.5)
|
12.1 (4.5)
|
11.8 (5.4)
|
11.4 (5.6)
|
11.6 (4.3)
|
11.2 (5.2)
|
11.9 (4.8)
|
|
CU-Q2oL Sleep Problems domain, n
|
80
|
77
|
80
|
81
|
79
|
82
|
82
|
79
|
83
|
252
|
|
Mean (SD)b
|
48.7 (23.6)
|
46.8 (22.7)
|
48.2 (25.2)
|
49.3 (22.9)
|
46.6 (19.9)
|
45.1 (22.6)
|
46.4 (23.7)
|
49.4 (21.1)
|
46.5 (21.8)
|
46.4 (21.5)
|
-
CU-Q
2
oL Chronic Urticaria Quality of Life Questionnaire, MOS-Sleep Scale Medical Outcomes Study Sleep Scale, SPI-II Sleep Problem Index II, UPDD Urticaria Patient Daily Diary
-
aNumber of patients: ASTERIA I: omalizumab 75 mg, n = 76; ASTERIA II: placebo, n = 78; GLACIAL: placebo, n = 82; omalizumab 300 mg, n = 250
-
bNumber of patients: ASTERIA I: placebo, n = 63; omalizumab 75 mg, n = 59; omalizumab 150 mg, n = 63; omalizumab 300 mg, n = 61; ASTERIA II: placebo, n = 69; omalizumab 75 mg, n = 70; omalizumab 150 mg, n = 70; omalizumab 300 mg, n = 71; GLACIAL: placebo, n = 79; omalizumab 300 mg, n = 243
